COVALON TECHS (CVALF) Stock News, May-Sep 2025

Covalon Technologies (OTCQX: CVALF) announced its participation in the Association for Vascular Access (AVA) Annual Scientific Meeting in Orlando from September 18-21, 2025. The company will showcase its vascular access and infection prevention solutions at Booth #515.

A recent peer-reviewed study from the Children's Hospital at Montefiore, published in JAVA, demonstrated that Covalon's VALGuard® Line Guard helped achieve a significant reduction in Central Line-Associated Blood Stream Infections (CLABSIs), including a period of zero CLABSIs in the Pediatric Critical Care Unit.

The company will feature three key products: VALGuard® Line Guard for IV line protection, CovaClear® dressings for IV securement, and IV Clear® dressings with antimicrobial protection, showcasing their integrated approach to infection prevention and line management.

Covalon Technologies (OTCQX: CVALF) announced significant results from a peer-reviewed clinical study of its VALGuard® Vascular Access Line Guard published in the Journal of the Association for Vascular Access. The study, conducted at the Children's Hospital at Montefiore, demonstrated remarkable effectiveness in reducing central line-associated bloodstream infections (CLABSIs).

The study revealed a 100% decrease in CLABSI rates in the Pediatric Critical Care Unit (PCCU), dropping from 1.8 CLABSIs per 1,000 line days to 0.0 over 16 months post-implementation. The Acute Care Units saw a 53% reduction in CLABSI rates, decreasing from 1.5 to 0.7 CLABSIs per 1,000 line days.

Covalon Technologies (OTCQX: CVALF) reported strong fiscal Q3 2025 results with sequential quarter-over-quarter revenue growth of 10.4% to $8.4 million and Adjusted EBITDA growth of 52% to $0.9 million. The company's trailing twelve months showed revenue growth of 13% and Adjusted EBITDA increase of 116%.

Key highlights include: U.S. Vascular Access and Surgical Consumables revenue up 35% YTD, Advanced Wound Care showing 40% sequential growth, and International sales up 35% YTD. The company maintains a strong balance sheet with $18 million in cash and no debt. Upcoming clinical evidence studies for VALGuard® Line Guard and CovaClear IV® products will be presented at major scientific meetings, expected to drive product adoption.

Covalon Technologies (TSXV: COV; OTCQX: CVALF), a medical technologies company, has achieved DTC eligibility for its shares in the United States, enabling electronic clearing and settlement on the OTCQX Market. This development streamlines trading processes and reduces transaction costs for U.S. investors.

The company also confirmed the previously announced appointment of Kim Crooks to its Board of Directors and the granting of 150,000 stock options at an exercise price of $2.50 per share. The options will vest over three years and expire in five years, subject to TSX Venture Exchange requirements and shareholder approval at the 2026 Annual General Meeting.

Covalon Technologies (OTCQX:CVALF), an advanced medical technologies company, has announced it will release its Q3 Fiscal 2025 financial results on Thursday, August 21, 2025, before markets open. The company will host a conference call and webcast to discuss the results at 8:30am ET on the same day.

Investors can participate via webcast or dial in using various phone numbers including North American Toll-Free: 1-800-549-8228. The conference call will include a Q&A session where participants can interact with company management. A recording will be available on Covalon's website afterward.

Covalon Technologies (OTCQX:CVALF), an advanced medical technologies company, has scheduled its Q3 Fiscal 2025 financial results announcement for Wednesday, August 21, 2025, before markets open.

The company will host a conference call and webcast at 8:30am ET on the same day to discuss the results. Participants can join via webcast or dial in using various phone numbers, including North American Toll-Free: 1-800-549-8228. The event will include a Q&A session where management will address questions from participants.

Covalon Technologies (CVALF) reported its fiscal 2025 Q2 results, marking its fifth consecutive quarter of profitability. Year-to-date revenue grew 21% to $15.7M, while Adjusted EBITDA increased by 57%. Q2 revenue was $7.6M, with a gross margin of 55%. The company's U.S. Vascular Access and Surgical Consumables segment showed 19% sequential quarterly growth and is up 46% year-to-date. International sales reached a 5-year high of $2.3M in Q2, growing 44% year-to-date. The company maintains a strong financial position with $18M in cash and no debt. Covalon recently signed a major distribution agreement with Paul Hartmann USA and has retained financial advisors to explore M&A opportunities. The company's North American manufacturing strategy has provided a competitive advantage in the current tariff environment.

Covalon Technologies (CVALF) has announced that results from a clinical study of its VALGuard® Vascular Access Line Guard will be presented at two major scientific meetings and is advancing towards publication. The independent study focused on reducing Central Line-Associated Blood Stream Infections (CLABSIs) across critical and acute care units. CLABSIs affect hundreds of thousands of patients annually with a 15-20% mortality rate. The research will be presented at the Association for Vascular Access Annual Scientific Meeting in September and the American Nurses Credentialing Center Magnet Pathway Conference in October, which attracts over 11,000 nursing professionals. Major U.S. hospitals are incorporating VALGuard® into their infection prevention programs to protect intravenous lines from contamination.

Covalon Technologies (TSXV: COV; OTCQX: CVALF), a medical technologies company, has scheduled the release of its Q2 Fiscal 2025 financial results for Wednesday, May 28, 2025, before markets open. The company will host a conference call and webcast at 8:30am ET on the same day to discuss the results.

Investors can participate through the webcast or by dialing into the conference call using the following numbers: North American Toll-Free: 1-800-549-8228, Toronto Local: 289-819-1520, or New York Local: 646-564-2877 (Conference ID: 92114). A recording will be available on Covalon's website, and financial statements can be accessed through SEDAR PLUS.